Novo Nordisk CEO Lars Fruergaard Jørgensen said Friday that the company’s experimental weight loss pill, Amycretin, “could develop into a best-in-class medicine.” His comments on CNBC came a day after the company’s stock surged following the announcement of promising results for the drug. That sent Novo Nordisk’s…
English (US)